Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)
Subtype terms (2)
More specific conditions that are subtypes of Iron Overload in the MeSH hierarchy.
- Hemochromatosis
13 drugs (7 approved, 6 experimental)
- Hemosiderosis
3 drugs approved
Drugs by status
Approved for this indication (3)
Phase 4 trials (3)
Phase 3 trials (7)
Phase 2 trials (6)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (13)
- Madaus Inc
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of Arizona
- Ain Shams University
- Annamalai University
- Consorzio per Valutazioni Biologiche e Farmacologiche
- University of Southern California
- University of Campinas
- Beni Suef University
- Isfahan University
- Ospedali Riuniti Villa Sofia-Cervello
- European Commission
- Maternity and Children Hospital, Makkah
Organization Involved with Phase 2 Indications (22)
- Shire
- Genzyme
- La Jolla Pharmaceutical Company
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Case Western Reserve University
- Harvard University
- Hacettepe University
- Northwestern University
- University of Milan
- University of Bari
- University of Bergen
- Leiden University
- Bar Ilan University
- University of Minnesota
- American University of Beirut
- University of Lille
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Genoa
- Fondazione Italiana Diabete Onlus
- Hangzhou Zede Pharma-Tech Co., Ltd.
- Abfero Pharmaceuticals, Inc
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (10)